Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cue Biopharma (CUE) EBITDA (2017 - 2025)

Cue Biopharma's EBITDA history spans 9 years, with the latest figure at -$7.4 million for Q3 2025.

  • For Q3 2025, EBITDA rose 14.01% year-over-year to -$7.4 million; the TTM value through Sep 2025 reached -$37.7 million, up 15.53%, while the annual FY2024 figure was -$40.7 million, 19.68% up from the prior year.
  • EBITDA for Q3 2025 was -$7.4 million at Cue Biopharma, up from -$8.5 million in the prior quarter.
  • Across five years, EBITDA topped out at -$7.4 million in Q3 2025 and bottomed at -$14.6 million in Q4 2022.
  • The 5-year median for EBITDA is -$12.3 million (2025), against an average of -$11.4 million.
  • The largest annual shift saw EBITDA crashed 74.09% in 2022 before it increased 29.31% in 2024.
  • A 5-year view of EBITDA shows it stood at -$8.4 million in 2021, then plummeted by 74.09% to -$14.6 million in 2022, then rose by 7.96% to -$13.4 million in 2023, then rose by 29.31% to -$9.5 million in 2024, then rose by 21.58% to -$7.4 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's EBITDA are -$7.4 million (Q3 2025), -$8.5 million (Q2 2025), and -$12.3 million (Q1 2025).